2012
Combined MEK and VEGFR Inhibition in Orthotopic Human Lung Cancer Models Results in Enhanced Inhibition of Tumor Angiogenesis, Growth, and Metastasis
Takahashi O, Komaki R, Smith PD, Jürgensmeier JM, Ryan A, Bekele BN, Wistuba II, Jacoby JJ, Korshunova MV, Biernacka A, Erez B, Hosho K, Herbst RS, O'Reilly MS. Combined MEK and VEGFR Inhibition in Orthotopic Human Lung Cancer Models Results in Enhanced Inhibition of Tumor Angiogenesis, Growth, and Metastasis. Clinical Cancer Research 2012, 18: 1641-1654. PMID: 22275507, PMCID: PMC3306446, DOI: 10.1158/1078-0432.ccr-11-2324.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsAntineoplastic Combined Chemotherapy ProtocolsBenzimidazolesCarcinoma, Non-Small-Cell LungCell Line, TumorCell ProliferationDisease ProgressionHumansLung NeoplasmsMaleMiceMice, NudeMitogen-Activated Protein KinasesMolecular Targeted TherapyNeovascularization, PathologicPaclitaxelProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)QuinazolinesRas ProteinsReceptors, Vascular Endothelial Growth FactorXenograft Model Antitumor AssaysConceptsSignal-regulated kinase kinaseTumor cell proliferationCell proliferationReceptor tyrosine kinasesKinase kinaseAvailable MEK1/2 inhibitorHuman NSCLC cellsTyrosine kinaseVEGF receptor tyrosine kinasesERK phosphorylationNCI-H441MEK1/2 inhibitorApoptotic effectsAdjacent normal tissuesKinaseNSCLC cellsMEK inhibitionAntiangiogenic effectsSignalingOrthotopic human lung cancer modelAvailable potent inhibitorLung tumor growthPotent inhibitorTumor angiogenesisSelumetinib
2002
Assessment of Antiangiogenic Effect Using 99mTc-EC-Endostatin
Yang DJ, Kim KD, Schechter NR, Yu DF, Wu P, Azhdarinia A, Roach JS, Kalimi SK, Ozaki K, Fogler WE, Bryant JL, Herbst R, Abbruzzes J, Kim EE, Podoloff DA. Assessment of Antiangiogenic Effect Using 99mTc-EC-Endostatin. Cancer Biotherapy & Radiopharmaceuticals 2002, 17: 233-246. PMID: 12030117, DOI: 10.1089/108497802753773856.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAnimalsAntineoplastic Combined Chemotherapy ProtocolsApoptosisCollagenCysteineEndostatinsEndothelial Growth FactorsFemaleFibroblast Growth Factor 2In Situ Nick-End LabelingIntercellular Signaling Peptides and ProteinsInterleukin-8LymphokinesMammary Neoplasms, ExperimentalNeovascularization, PathologicPaclitaxelPeptide FragmentsRadionuclide ImagingRatsRats, Inbred F344TechnetiumTumor Cells, CulturedVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsTumor-bearing ratsAnti-angiogenesis therapyTreatment responseTumor uptakeTUNEL assayAnti-angiogenic treatment responseTumor vascular densityIL-8 expressionTumor-bearing animal modelsCount density ratiosCell viabilityPrognostic indicatorMicrovessel densityVascular densityAnimal modelsEndostatin therapyAntiangiogenic effectsMetastatic potentialTherapyUptake doseCellular uptake assaysEndostatinTissue distributionRatsEthylenedicysteine
2001
Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck
Tseng J, Glisson B, Khuri F, Shin D, Myers J, El‐Naggar A, Roach J, Ginsberg L, Thall P, Wang X, Teddy S, Lawhorn K, Zentgraf R, Steinhaus G, Pluda J, Abbruzzese J, Hong W, Herbst R. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 2001, 92: 2364-2373. PMID: 11745292, DOI: 10.1002/1097-0142(20011101)92:9<2364::aid-cncr1584>3.0.co;2-p.Peer-Reviewed Original ResearchConceptsMetastatic squamous cell carcinomaSquamous cell carcinomaPhase II studyCell carcinomaProgressive diseaseII studySurvival timeAntiangiogenic effectsAdvanced squamous cell carcinomaBasic fibroblast growth factor levelsMedian overall survival timeFibroblast growth factor levelsSingle-agent thalidomideSingle-agent antitumor activityEarly-stage diseasePopulation of patientsOverall survival timeGrowth factor levelsVascular endothelial growth factorMinimal residual diseaseSignificant antitumor effectEndothelial growth factorMechanism of actionStage diseaseUnacceptable toxicity